Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Novel Filtration System Removes Proteins and Phospholipids from Analytical Samples

By BiotechDaily International staff writers
Posted on 03 Feb 2014
Image: The ISOLUTE PLD+ protein and phospholipid removal plate (Photo courtesy of Biotage).
Image: The ISOLUTE PLD+ protein and phospholipid removal plate (Photo courtesy of Biotage).
Biotechnology and other life science researchers now have available a novel filter system that removes both proteins and phospholipids, which leaves samples ready for LC-MS/MS (liquid chromatography-mass spectroscopy) analysis.

The Biotage (Uppsala, Sweden) ISOLUTE PLD+ plate combines protein and phospholipid removal from blood-based matrix samples and provides simple and effective cleanup for LC-MS/MS analysis. According to the manufacturer, ISOLUTE PLD+ plates remove more than 99% of plasma proteins and phospholipids, the main causes of ion suppression, leading to cleaner extracts and increased sensitivity, signal-to-noise, for a broad range of analytes.

ISOLUTE PLD+ plates are available in standard 96-well format and can handle sample volumes of 100 to 200 microliters. Operation of the ISOLUTE PLD+ plate includes a filtration step that can be accomplished with a 96-well compatible positive pressure manifold (such as the Biotage Pressure+ 96), a vacuum manifold (for example the Biotage VacMaster 96) and most automated liquid handling systems.

“Requiring next to no method development, ISOLUTE PLD+ can be integrated quickly and easily into routine workflow, increasing productivity and reducing instrument downtime,” said Paul Roberts, analytical product manager at Biotage.

Related Links:

Biotage



Channels

Genomics/Proteomics

view channel
Image: The bone marrow of mice with normal ether lipid production (top) contains more white blood cells than are found in the bone marrow of mice with ether lipid deficiency (bottom) (Photo courtesy of Washington University School of Medicine).

Inactivating Fatty Acid Synthase Reduces Inflammation by Interfering with Neutrophil Membrane Function

The enzyme fatty acid synthase (FAS) was shown to regulate inflammation by sustaining neutrophil viability through modulation of membrane phospholipid composition. Neutrophils are the most abundant... Read more

Drug Discovery

view channel
Image: Researchers have attached two drugs—TRAIL and Dox—onto graphene strips. TRAIL is most effective when delivered to the external membrane of a cancer cell, while Dox is most effective when delivered to the nucleus, so the researchers designed the system to deliver the drugs sequentially, with each drug hitting a cancer cell where it will do the most damage (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Anticancer Drug Delivery System Utilizes Graphene Strip Transporters

The ongoing search by cancer researchers for targeted drug delivery systems has generated a novel approach that uses graphene strips to transport simultaneously the anticancer agents TRAIL (tumor necrosis... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Business

view channel

Biotech Acquisition Designed to Accelerate the Development and Marketing of Immunosequencing Applications

Adaptive Biotechnologies Corp. (Seattle, WA, USA), a developer of next-generation sequencing (NGS) to profile T-cell and B-cell receptors, has acquired of Sequenta, Inc. (South San Francisco, CA, USA), which is expected to expedite and expand the use of innovative immunosequencing technology for researchers and clinicians... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.